Vo2peak in Adult Survivors of Hodgkin Lymphoma

Rizwan, Raheel; Vinograd, Cheryl A.; Yamada, Jessica M; Mangano, Christina Mora; Ng, Andrea K.; Alexander, Mark E.; Chen, Ming Hui

doi:10.1016/j.jaccao.2021.04.010

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45,46 Exercise stress testing has also shown progressive decline in measured exercise capacity (peak Vo 2 ). 47,48 Survivors also have an increased rates of hypertension, dyslipidemia, and vascular disease compared with the general population that may be exacerbated by environmental exposures and behaviors such as exercise, diet, and tobacco use. [42][43][44][45][46][47][48] Because of the inherent challenges faced by many childhood cancer survivors, who often are faced with strong desires to minimize medical care and to reflect peers without cancer histories, we suggest that an enhanced focus on the need for consistent care should be delivered to both patients and facilities.…”

Section: Cardiotoxicity In Pediatric Populationsmentioning

confidence: 99%

Equity in Cardio-Oncology Care and Research: A Scientific Statement From the American Heart Association

Morrison¹,

Baik²,

Fradley³

et al. 2023

Circulation

View full text Add to dashboard Cite

Advances in cancer therapeutics have revolutionized survival outcomes in patients with cancer. However, cardiovascular toxicities associated with specific cancer therapeutics adversely affect the outcomes of patients with cancer. Recent studies have uncovered excess risks of these cardiotoxic events, especially in traditionally underrepresented populations. Despite advances in strategies to limit the risks of cardiovascular events among cancer survivors, relatively limited guidance is available to address the rapidly growing problem of disparate cardiotoxic risks among women and underrepresented patient populations. Previously decentralized and sporadic evaluations have led to a lack of consensus on the definitions, investigation, and potential optimal strategies to address disparate cardiotoxicity in contemporary cancer care (eg, with immunotherapy, biologic, or cytotoxic therapies) settings. This scientific statement aims to define the current state of evidence for disparate cardiotoxicity while proposing uniform and novel methodological approaches to inform the identification and mitigation of disparate cardio-oncology outcomes in future clinical trials, registries, and daily clinical care settings. We also propose an evidence-based integrated approach to identify and mitigate disparities in the routine clinical setting. This consensus scientific statement summarizes and clarifies available evidence while providing guidance on addressing inequities in the era of emerging anticancer therapies.

show abstract